Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
Aclarion signed a second commercial agreement with Weill Cornell Medicine to utilize its Nociscan platform in a prospective randomized trial focused on degenerative disc disease. The study, led by neurosurgeon Dr. Roger Härtl, will evaluate long-term effects of lumbar surgery with bone marrow aspirate concentrate to better understand disc health and pain biomarkers over a two-year period.
Key figures
- Global sufferers
- 266000000
- Surgical success rate
- 97%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.